

# Robin Condcliffe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4067658/publications.pdf>

Version: 2024-02-01

97  
papers

7,048  
citations

109321  
35  
h-index

60623  
81  
g-index

98  
all docs

98  
docs citations

98  
times ranked

7029  
citing authors

#	ARTICLE	IF	CITATIONS
1	Definitions and Diagnosis of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D42-D50.	2.8	1,467
2	Connective Tissue Disease-associated Pulmonary Arterial Hypertension in the Modern Treatment Era. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 151-157.	5.6	576
3	Changing Demographics, Epidemiology, and Survival of Incident Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 790-796.	5.6	483
4	Improved Outcomes in Medically and Surgically Treated Chronic Thromboembolic Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1122-1127.	5.6	379
5	Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy. Circulation, 2016, 133, 1761-1771.	1.6	307
6	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nature Communications, 2018, 9, 1416.	12.8	279
7	Respiratory follow-up of patients with COVID-19 pneumonia. Thorax, 2020, 75, 1009-1016.	5.6	266
8	An official European Respiratory Society statement: pulmonary haemodynamics during exercise. European Respiratory Journal, 2017, 50, 1700578.	6.7	222
9	Pulmonary hypertension in COPD: results from the ASPIRE registry. European Respiratory Journal, 2013, 41, 1292-1301.	6.7	173
10	Discovery of Distinct Immune Phenotypes Using Machine Learning in Pulmonary Arterial Hypertension. Circulation Research, 2019, 124, 904-919.	4.5	141
11	Noninvasive Estimation of PA Pressure, Flow, and Resistance With CMR Imaging. JACC: Cardiovascular Imaging, 2013, 6, 1036-1047.	5.3	129
12	Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 228-239.	5.6	122
13	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine, 2019, 7, 227-238.	10.7	122
14	Pulmonary hypertension: diagnosis and management. BMJ, 2013, 346, f2028-f2028.	6.0	119
15	Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. Circulation, 2017, 136, 2022-2033.	1.6	111
16	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respiratory Medicine, 2017, 5, 717-726.	10.7	99
17	Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 458-468.	5.6	99
18	British Thoracic Society Clinical Statement on Pulmonary Arteriovenous Malformations. Thorax, 2017, 72, 1154-1163.	5.6	94

#	ARTICLE	IF	CITATIONS
19	The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2018, 52, 1800589.	6.7	87
20	LGE Patterns in Pulmonary Hypertension Do Not Impact Overall Mortality. JACC: Cardiovascular Imaging, 2014, 7, 1209-1217.	5.3	82
21	Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 575-585.	5.6	80
22	Experimental validation of the hyperpolarized <sup>129</sup> Xe chemical shift saturation recovery technique in healthy volunteers and subjects with interstitial lung disease. Magnetic Resonance in Medicine, 2015, 74, 196-207.	3.0	76
23	Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. Journal of Heart and Lung Transplantation, 2017, 36, 770-779.	0.6	73
24	Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension. JACC: Cardiovascular Imaging, 2021, 14, 931-942.	5.3	73
25	Pulmonary Artery Denervation Reduces Pulmonary Artery Pressure and Induces Histological Changes in an Acute Porcine Model of Pulmonary Hypertension. Circulation: Cardiovascular Interventions, 2015, 8, e002569.	3.9	66
26	Management dilemmas in acute pulmonary embolism. Thorax, 2014, 69, 174-180.	5.6	60
27	British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE). Thorax, 2018, 73, ii1-ii29.	5.6	58
28	Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet Respiratory Medicine, 2022, 10, 937-948.	10.7	57
29	Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. Chest, 2017, 152, 92-102.	0.8	53
30	BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?. European Respiratory Review, 2020, 29, 200009.	7.1	51
31	Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2020, 55, 2000041.	6.7	48
32	Perioperative management of patients with pulmonary hypertension undergoing non-cardiothoracic, non-obstetric surgery: a systematic review and expert consensus statement. British Journal of Anaesthesia, 2021, 126, 774-790.	3.4	45
33	Diagnosis of Pulmonary Hypertension with Cardiac MRI: Derivation and Validation of Regression Models. Radiology, 2019, 290, 61-68.	7.3	43
34	Connective tissue disease-associated pulmonary arterial hypertension. F1000prime Reports, 2015, 7, 06.	5.9	41
35	Echocardiographic Screening for Pulmonary Hypertension in Congenital Heart Disease. Journal of the American College of Cardiology, 2018, 72, 2778-2788.	2.8	38
36	Pregnancy and pulmonary hypertension: a practical approach to management. Obstetric Medicine, 2013, 6, 144-154.	1.1	36

#	ARTICLE	IF	CITATIONS
37	Right Ventricular Sex Differences in Patients with Idiopathic Pulmonary Arterial Hypertension Characterised by Magnetic Resonance Imaging: Pair-Matched Case Controlled Study. PLoS ONE, 2015, 10, e0127415.	2.5	33
38	CT pulmonary angiography combined with echocardiography in suspected systemic sclerosis-associated pulmonary arterial hypertension. Rheumatology, 2011, 50, 1480-1486.	1.9	32
39	Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: a UK cohort study analysis. European Respiratory Journal, 2019, 53, 1801429.	6.7	31
40	The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension. Thorax, 2017, 72, 1035-1045.	5.6	30
41	A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. EBioMedicine, 2021, 69, 103444.	6.1	30
42	Pulmonary Artery Size in Interstitial Lung Disease and Pulmonary Hypertension: Association with Interstitial Lung Disease Severity and Diagnostic Utility. Frontiers in Cardiovascular Medicine, 2018, 5, 53.	2.4	29
43	Bayesian Inference Associates Rare <i>KDR</i> Variants With Specific Phenotypes in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2021, 14, .	3.6	29
44	Diagnostic accuracy of CT pulmonary angiography in suspected pulmonary hypertension. European Radiology, 2020, 30, 4918-4929.	4.5	29
45	EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study. European Respiratory Journal, 2021, 57, 2000124.	6.7	29
46	Supplementation with Iron in Pulmonary Arterial Hypertension. Two Randomized Crossover Trials. Annals of the American Thoracic Society, 2021, 18, 981-988.	3.2	28
47	Elevated Plasma CXCL12 Is Associated with a Poorer Prognosis in Pulmonary Arterial Hypertension. PLoS ONE, 2015, 10, e0123709.	2.5	27
48	Identifying At-Risk Patients with Combined Pre- and Postcapillary Pulmonary Hypertension Using Interventricular Septal Angle at Cardiac MRI. Radiology, 2018, 289, 61-68.	7.3	27
49	Pulmonary hypertension phenotypes in patients with systemic sclerosis. European Respiratory Review, 2021, 30, 210053.	7.1	27
50	Serum Osteoprotegerin is Increased and Predicts Survival in Idiopathic Pulmonary Arterial Hypertension. Pulmonary Circulation, 2012, 2, 21-27.	1.7	24
51	Pulmonary arterial hypertension associated with congenital heart disease: Comparison of clinical and anatomic pathophysiologic classification. Journal of Heart and Lung Transplantation, 2016, 35, 610-618.	0.6	21
52	Pulmonary Hypertension in Patients with Heart Failure and Preserved Ejection Fraction: Differential Diagnosis and Management. Pulmonary Circulation, 2016, 6, 3-14.	1.7	20
53	Pathophysiology and Diagnosis of Pulmonary Hypertension Due to Left Heart Disease. Frontiers in Medicine, 2018, 5, 174.	2.6	20
54	Circulating Protein Biomarkers in Systemic Sclerosis Related Pulmonary Arterial Hypertension: A Review of Published Data. Frontiers in Medicine, 2018, 5, 175.	2.6	19

#	ARTICLE	IF	CITATIONS
55	Homozygous <i>GDF2</i> nonsense mutations result in a loss of circulating BMP9 and BMP10 and are associated with either PAH or an "HHT-like" syndrome in children. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2021, 9, e1685.	1.2	19
56	Incremental shuttle walk test distance and autonomic dysfunction predict survival in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 871-879.	0.6	16
57	Idiopathic pulmonary arterial hypertension and coexisting lung disease: is this a new phenotype?. <i>Pulmonary Circulation</i> , 2020, 10, 1-8.	1.7	16
58	Critical care outcomes in patients with pre-existing pulmonary hypertension: insights from the ASPIRE registry. <i>ERJ Open Research</i> , 2021, 7, 00046-2021.	2.6	15
59	Pulmonary Hypertension in Association with Lung Disease: Quantitative CT and Artificial Intelligence to the Rescue? State-of-the-Art Review. <i>Diagnostics</i> , 2021, 11, 679.	2.6	15
60	Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre. <i>Therapeutic Advances in Respiratory Disease</i> , 2014, 8, 71-77.	2.6	13
61	Maximal Exercise Testing Using the Incremental Shuttle Walking Test Can Be Used to Risk-Stratify Patients with Pulmonary Arterial Hypertension. <i>Annals of the American Thoracic Society</i> , 2021, 18, 34-43.	3.2	13
62	Repeatability and sensitivity to change of non-invasive end points in PAH: the RESPIRE study. <i>Thorax</i> , 2021, 76, 1032-1035.	5.6	13
63	Long-term outcomes of domiciliary intravenous iloprost in idiopathic and connective tissue disease-associated pulmonary arterial hypertension. <i>Respirology</i> , 2017, 22, 372-377.	2.3	12
64	Mildly increased pulmonary arterial pressure: a new disease entity or just a marker of poor prognosis?. <i>European Journal of Heart Failure</i> , 2019, 21, 1057-1061.	7.1	11
65	Right Ventricular Adaptation Assessed Using Cardiac Magnetic Resonance Predicts Survival in Pulmonary Arterial Hypertension. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1271-1272.	5.3	11
66	Machine learning cardiac-MRI features predict mortality in newly diagnosed pulmonary arterial hypertension. <i>European Heart Journal Digital Health</i> , 2022, 3, 265-275.	1.7	11
67	Partial anomalous pulmonary venous drainage in patients presenting with suspected pulmonary hypertension: A series of 90 patients from the ASPIRE registry. <i>Respirology</i> , 2020, 25, 1066-1072.	2.3	10
68	Adults' experiences of living with pulmonary hypertension: a thematic synthesis of qualitative studies. <i>BMJ Open</i> , 2020, 10, e041428.	1.9	10
69	Severe pulmonary hypertension associated with lung disease is characterised by a loss of small pulmonary vessels on quantitative computed tomography. <i>ERJ Open Research</i> , 2022, 8, 00503-2021.	2.6	10
70	Palliative care in pulmonary hypertension associated with congenital heart disease: systematic review and expert opinion. <i>ESC Heart Failure</i> , 2021, 8, 1901-1914.	3.1	9
71	Training and clinical testing of artificial intelligence derived right atrial cardiovascular magnetic resonance measurements. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2022, 24, 25.	3.3	8
72	Effect of dual pulmonary vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease: a retrospective analysis. <i>Open Heart</i> , 2016, 3, e000399.	2.3	7

#	ARTICLE	IF	CITATIONS
73	Pulmonary arteriovenous malformations emerge from the shadows. <i>Thorax</i> , 2017, 72, 1071-1073.	5.6	7
74	Management of Adults With Congenital Heart Disease and Pulmonary Arterial Hypertension in the UK: Survey of Current Practice, Unmet Needs and Expert Commentary. <i>Heart Lung and Circulation</i> , 2018, 27, 1018-1027.	0.4	7
75	The incremental shuttle walk test predicts mortality in nonâ€‘group 1 pulmonary hypertension: results from the ASPIRE Registry. <i>Pulmonary Circulation</i> , 2019, 9, 1-9.	1.7	7
76	Computed tomography lung parenchymal descriptions in routine radiological reporting have diagnostic and prognostic utility in patients with idiopathic pulmonary arterial hypertension and pulmonary hypertension associated with lung disease. <i>ERJ Open Research</i> , 2022, 8, 00549-2021.	2.6	7
77	Imaging and Risk Stratification in Pulmonary Arterial Hypertension: Time to Include Right Ventricular Assessment. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 797561.	2.4	7
78	Unmasking hidden disease: exercise pulmonary haemodynamics in systemic sclerosis. <i>European Respiratory Journal</i> , 2017, 50, 1700885.	6.7	6
79	The use of Macitentan in Fontan circulation: a case report. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 131.	1.7	6
80	Identifying early pulmonary arterial hypertension in patients with systemic sclerosis. <i>European Respiratory Journal</i> , 2018, 51, 1800495.	6.7	6
81	Assessing pulmonary hypertension severity in lung disease is a key step to improving outcomes: embrace resistance and don't be pressurised to go with the flow. <i>European Respiratory Journal</i> , 2021, 58, 2102008.	6.7	6
82	Combining creative writing and narrative analysis to deliver new insights into the impact of pulmonary hypertension. <i>BMJ Open Respiratory Research</i> , 2017, 4, e000184.	3.0	4
83	Incremental Shuttle Walking Test Distance Is Reduced in Patients With Pulmonary Hypertension in World Health Organisation Functional Class I. <i>Frontiers in Medicine</i> , 2018, 5, 172.	2.6	4
84	Decision-making in pulmonary endarterectomy surgery. <i>European Respiratory Journal</i> , 2019, 53, 1801973.	6.7	3
85	Mild parenchymal lung disease is still lung disease. <i>European Respiratory Journal</i> , 2020, 56, 2003727.	6.7	3
86	Examining the impact of pulmonary hypertension on nonprofessional caregivers: A mixedâ€‘methods systematic review. <i>Pulmonary Circulation</i> , 2022, 12, e12077.	1.7	3
87	Management of acute pulmonary embolism. <i>British Journal of Hospital Medicine (London, England:)</i> Tj ETQq1 1 0.784314 rgBT /Overl	0.5	2
88	Pulmonary arterial hypertension in adults with congenital heart disease: markers of disease severity, management of advanced heart failure and transplantation. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 837-855.	1.5	2
89	Unenhanced computed tomography as a diagnostic tool in suspected pulmonary hypertension: a retrospective cross-sectional pilot study. <i>Wellcome Open Research</i> , 0, 6, 249.	1.8	2
90	Elective lower limb orthopedic arthroplasty surgery in patients with pulmonary hypertension. <i>Pulmonary Circulation</i> , 2022, 12, e12019.	1.7	2

#	ARTICLE	IF	CITATIONS
91	CMR Measures of Left Atrial Volume Index and Right Ventricular Function Have Prognostic Value in Chronic Thromboembolic Pulmonary Hypertension. <i>Frontiers in Medicine</i> , 2022, 9, 840196.	2.6	2
92	Management of Suspected Chronic Thromboembolic Pulmonary Hypertension. , 0, , 405-420.		1
93	Survival in Pulmonary Hypertension Registries. <i>Chest</i> , 2011, 139, 1547-1548.	0.8	1
94	Diagnostic and prognostic value of a diagnostic CT regression model in suspected pulmonary hypertension. , 2019, , .		1
95	Congenital heart disease, pulmonary arterial hypertension and the UK's Drivers and Vehicle Licensing Agency: controversial new guidance. <i>Pulmonary Circulation</i> , 2019, 9, 1-2.	1.7	0
96	Establishing expert consensus for the optimal approach to holistic risk-management in pulmonary arterial hypertension: a Delphi process and narrative review. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1493-1503.	2.5	0
97	Comment on "External validation of the OPALS prediction model for in-hospital mortality in patients with acute decompensated pulmonary hypertension". <i>ERJ Open Research</i> , 2022, 8, 00066-2022.	2.6	0